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Abstract
Taurine supplementation has been shown to have a beneficial effect on femur bone mineral content in ovariectomized rats. It therefore seemed
desirable to find out whether the beneficial effect of taurine on ovariectomized rats fed calcium deficient diet could also be reproduced. Forty female
Sprague-Dawley rats were divided into two groups. One group was OVX and the other group received sham operation (SHAM), and received either
control diet or a taurine supplemented diet for 6 weeks. All rats were fed on calcium deficient diet (AIN-93: 50% level of calcium) and deionized
water. Bone mineral density (BMD) and bone mineral content (BMC) were measured in spine and femur. The serum and urine concentrations of
calcium and phosphorus were determined. Bone formation was measured by serum osteocalcin and alkaline phosphatase (ALP) concentrations. Bone
resorption rate was measured by deoxypyridinoline (DPD) crosslinks immunoassay and corrected for creatinine. Urinary calcium and  phosphorus
excretion, osteocalcin in blood and cross link value were not significantly different among the groups. Within the OVX group, the taurine supplemented 
group had not higher femur bone mineral content than the control group. This study established the need for a study on the taurine effect on
bone with different calcium levels.
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Introduction6)
Adequate amounts of calcium are essential throughout the life 
cycle to promote bone and overall health, and to help reduce 
the risk of osteoporosis (Nieves, 2005). Osteoporosis is 
considered a major public health threat for an estimated 44 
million U.S. women and men 50 y old, causing an annual health 
care cost of $17 billion in 2001 (McCarron & Heaney, 2004). 
Unfortunately, children, adolescents, especially girls, do not 
consume the recommended 2-3 servings of milk and milk 
products each day (Fiorito et al., 2006). As a result of declining 
milk consumption in recent years, 70% of girls aged 6-11 y does 
not meet current calcium recommendations (Fiorito et al., 2006).
Osteoporosis and osteoporotic fractures have substantial clinical 
and health effects. An estimated 75 million persons in Europe, 
Japan, and the United States are affected by osteoporosis (Report 
of a WHO Scientific Group, 2003). Osteoporosis is characterized 
by low bone density and microarchitectural deterioration of bone 
tissue, and there is increasing interest in environmental factors 
that may influence bone density. Nutrition clearly plays a role; 
nutrient inadequacies, eg, calcium and vitamin D, have received 
the most emphasis (Gourlay & Brown, 2004; Heaney et al., 2002; 
Ilich & Kerstetter, 2000). Dairy consumption has been postulated 
to reduce the risk of osteoporosis and metabolic disturbances. 
Several observational studies have found associations between 
calcium intake or intake of dairy products and bone mineral 
density.  The recommended calcium intake changes with age 
(Institute of Medicine, 1997). One of the highest daily intakes 
is required after age 50. Important dietary sources of calcium 
are dairy products (milk, yogurt, and cheese), dark green 
vegetables; canned fish with bones (but not fish fillets); nuts; 
and more recently, fortified foods (including juices, waffles, 
cereals, crackers, and snack foods). A large proportion of the 
worlds' population consumes low-calcium diets. Women in 
developed nations, such as the United States and northern Europe, 
where the incidence of osteoporosis is high, generally have 
inadequate calcium status. 
Of the nutrients, calcium has been the most extensively studied 
to determine its role in osteoporosis. Approximately, 99% of the 
body's calcium is stored in the bone as hydroxyapatite, which 
provides structural integrity for the skeleton (Broadus, 1993). 
Vitamin D may play a role in the development of osteoporosis due 
to its effect on calcium metabolism. Plasma calcium homeostasis 
is maintained by vitamin D in conjunction with PTH. Low blood 
calcium level activates PTH, which in turn stimulates the 
production of vitamin D in the kidney. In response, vitamin D 
enhances the absorption of calcium, decreases the excretion of 
calcium and stimulates calcium resorption from bone (Linder, 1991). 
Human growth hormone (hGH) has been shown in some studies 
to have anabolic effects on bone but taurine effects on bone are 
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Table 1. Composition of experimental diets (g/100 g diet) 
Ingredients Control Taurine
Casein
1) 20 20
Corn starch
2) 52.9486 52.9486
Sucrose 10 10
Soybean oil 7 7
Cellulose
3) 55
Min-mix
4) 3.5 3.5
Vit-mix
5) 1.0 1.0
L-cystine 0.30 0.30
Choline
6) 0.25 0.25
Tert-butyl hydroquinone 0.0014 0.0014
Taurine
7) -2 . 0
1) Lactic  Casein,  30  mesh,  New  Zealand  Dairy  Board,  Willington,  N.Z. 
2) Corn Starch, Doosan Co. 234-17 Maam-Ri, Bubal-Eup, Inchon-City, Kyunggi-do 
3) Cellulose,  supplied  by  SIGMA  Chemical  Company.  No.C8002 
4) Calcium  deficient  mineral  mixture  (AIN-93G),  supplied  by  U.S.  CORNING 
Laboratory  Services,  Company.  TEKLAD  TEST  DIETS,  Madison,  Wisconsin
5) Vitamin  mixture  (AIN-93),  supplied  by  U.S.  CORNING  Laboratory  Services 
Company.  TEKLAD  TEST  DIETS,  Madison,  Wisconsin
6) Choline,  supplied  by  SIGMA  Chemical  Company.  No.C1629 
7) Taurine, Dong-A Pharm. Co. Ltd. 434-4 Moknae-dong, Ansan-City,  Kyunggi-do 
unknown. The major hormones that regulate tissue growth and 
metabolism all have a major influence on skeletal growth and 
remodeling, including the growth hormone-insulin-like growth 
factor (GH-IGH) system. The GH-IGH system determines body 
size and regulates the distribution of body fat, lean body mass, 
and bone modeling and remodeling after epiphyseal closures 
(Sjogren et al., 1999). GH can stimulate IGF production not only 
in the liver but also in other target organs, including bone. The 
GH-IGF system stimulates both resorption and formation (Yakar 
et al., 2002).
Taurine could act either directly or indirectly by enhancing 
growth factor production (Boujendar et al., 2002). However, no 
significant association between taurine intake and spine or femur 
bone mineral density was observed. An association between 
taurine intake and bone turnover markers was also not found. 
The present study is unique in that it investigated the relations 
of taurine and bone. Influence of taurine on early postmenopausal 
bone loss is not well understood. Dietary supplement with excess 
taurine could yield increased sulfuric acid production in the body. 
Under those circumstances, the skeleton may be called on to act 
as a buffer to neutralize acid generated from high-sulfuric diets. 
On the other hand, interest has been expressed in the relation 
of skeletal maintenance to age-related decreases in IGF-I 
concentrations (Jensen et al., 2002). Recombinant IGF-I increases 
bone formation activity in postmenopausal women (Ebeling et 
al., 1993; Ghiron et al., 1995; Grinspoon et al., 1995), suggesting 
that increasing IGF-I concentrations may help restore bone mass. 
IGF-I production is markedly affected by nutrient intake (Jensen 
et al., 2002). The paper recently demonstrated that taurine 
supplementation of the maternal diet restored normal IGF-II 
expression in islet cells of fetuses of low protein-fed rats 
(Boujendar  et al., 2002). Our understanding of how taurine 
affects calcium homeostasis and skeletal metabolism is limited.
Low calcium diets can produce rachitic lesions in young growing 
animals, but in adults the condition becomes osteoporosis. It has 
been reported that calcium deficient, ovariectomized rats develop 
bone changes (especially decrease in bone density) similar to 
estrogen deficient osteoporotic women (Donahue et al., 1988).
Therefore, we examined in ovariectomized rats whether the 
preventive effect of taurine on ovarian hormone deficiency- 
induced bone loss. Taurine supplementation has been shown to 
have an effect on femur bone mineral content in ovariectomized 
rats in our research (Choi & DiMarco, 2009). It therefore seemed 
desirable to find out whether the beneficial effect of taurine on 
OVX rats fed calcium deficient diet could also be reproduced. 
Materials and Methods
Animals and diet
Forty female Sprague-Dawley rats (body weight 200 ± 5 g, 9 
weeks old) were randomly divided into two groups. One group 
was ovariectomized (OVX) and the other group received sham 
operation (SHAM), and then each rat group was further divided 
into control diet and taurine supplemented (2.0%) diet group for 
6 weeks. All rats were fed on experimental diet and deionized 
water ad libitum for 6 weeks. The rats were weighed weekly. 
The dietary supply of vitamins, minerals (except Ca : 50% of 
recommended level ), and protein was in accordance with the 
recommended dietary allowances for rats from the American 
Institute of Nutrition (AIN-93G; Reeves et al., 1993) and shown 
in Table 1. 
Bone and bone markers determination
Bone mineral density (BMD) and bone mineral content (BMC) 
were measured using PIXImus (GE Lunar Co, Wisconsin, USA) 
in spine and femur on 6 weeks after feeding. Bone formation 
was measured by serum osteocalcin and alkaline phosphatase 
(ALP) concentrations. Bone resorption was measured by 
deoxypyridinoline (DPD) crosslinks immunoassay and corrected 
for creatinine. Serum osteocalcin, growth hormone, insulin-like 
growth factor-1 (IGF-1), parathyroid hormone (PTH) and 
calcitonin were analyzed using radioimmunoassay kits. 
Statistical analysis 
The statistical significance of differences among the groups 
was evaluated by two-way ANOVA, using a computer software 
package (version 9.13, SAS Institute Inc, Cary, NC). Individual 
comparisons were made by Duncan's multiple range test using 
the ANOVA. A P value <0.05 was considered statistically 
significant. Data are expressed as means ± SD.110 Effect of taurine on BMD in OVX rats fed low Ca
Table 2. The effect of diets on body weight, food intake, and FER in rats fed
Ca deficient diet*
Sham Ovx
Control Taurine Control Taurine
Initial weight (g) 185.4 ± 8.1
1)a2) 184.1 ± 9.8
a  192.5 ± 10.7
a  192.7 ± 9.8
a
Final weight (g) 239.6 ± 13.7
b 257.3 ± 33.5
b  304.6 ± 15.3
a  307.2 ± 13.3
a
Weight gain (g) 61.64 ± 17.99
b 79.68 ± 35.79
b 119.21 ± 21.07
a 122.21 ± 14.38
a
Food intake (g) 14.52 ± 3.85
a 13.81 ± 1.73
a  16.78 ± 0.80
a  16.57 ± 0.74
a
FER  0.10 ± 0.02
c  0.13 ± 0.04
bc   0.16 ± 0.03
ba   0.17 ± 0.02
a
1) Mean ± SD
2) Values  with  different  superscript  within  a  column  are  significantly  different  at 
p<0.05  by  Duncan's  multiple  range  test.
*T a b l e  2  i s  p u b l i s h e d  in  t h e  p r e v i o u s  s t u d y  ( C h o i ,  2 0 0 8 ) .
Table 3. The effect of diets on serum Ca and P in rats fed Ca deficient diet 
with taurine supplementation
Sham Ovx
Control Taurine Control Taurine
Ca (mg/dl) 9.56 ± 0.59
1)a2) 9.44 ± 0.18
a 9.70 ± 0.25
a 9.86 ± 0.36
a
P (mg/dl) 6.46 ± 1.48
a 6.66 ± 0.50
a 6.76 ± 0.29
a 6.58 ± 0.43
a
1) Mean ± SD
2) Values  with  different  superscript  within  a  column  are  significantly  different  at 
p<0.05  by  Duncan's  multiple  range  test.
Table 4. The effects of diets on values of serum alkaline phosphatase (ALP) 
and osteocalcin in rats fed Ca deficient diet with taurine supplementation
Sham Ovx
Control  Taurine Control Taurine
ALP (u/l) 291.8±84.2
1)a2) 299.8 ± 42.1
a 341.2 ± 39.3
a 330.2 ± 64.1
a
Osteocalcin
(ng/ml)
 3.37 ± 3.334
a 6.567 ± 2.496
a 2.338 ± 1.531
a 5.993 ± 3.359
a
1) Mean ± SD
2) Values  with  different  superscript  within  a  column  are  significantly  different  at 
p<0.05  by  Duncan's  multiple  range  test.
Table 5. The effect of taurine on urinary Ca and P excretion in OVX rats
Sham Ovx
Control Taurine Control Taurine
Ca (mg/day) 0.20 ± 0.12
1)a2) 0.23 ± 0.08
a  0.22 ± 0.11
a  0.24 ± 0.13
a
P (mg/day) 8.23 ± 3.22
a 7.32 ± 2.79
a 11.12 ± 3.56
a 13.43 ± 3.47
a
1) Mean ± SD
2) Values with different superscript within a raw are significantly different at p<0.05 
by  Duncan's  multiple  range  test.
Table 6. The effect of taurine on urine deoxypyridinoline, creatinine and 
crosslink value in rats
Sham Ovx
Control Taurine Control Taurine
DPD (nM) 766.5 ± 379.4
1)a2) 783.2 ± 341.9
a 910.3 ± 466.5
a 993.8 ± 345.4
a
Creatinine 
(mM)
 4.20 ± 1.71
a  4.60 ± 7.11
a  4.44 ± 2.09
a  5.82 ± 4.97
a
Crosslink 
value (nM/mM)
164.4 ± 26.8
a 169.3 ± 36.9
a  278 ± 73.5
b 245.5 ± 22.7
b
1) Mean ± SD
2) Values with different superscript within a raw are significantly different at p<0.05 
by  Duncan's  multiple  range  test.
Table 7. The effect of diets on spine BMD and BMC, and spine BMD per weight
and BMC per weight in rats fed Ca deficient diet
Sham Ovx
Control Taurine Control Taurine
SBMD (g/cm
2) 0.095 ± 0.010
1)a2) 0.094 ± 0.011
a 0.084 ± 0.008
b 0.081 ± 0.005
b
SBMD (g/cm
2)
/wt (kg)
 0.51 ± 0.001
a  0.52 ± 0.001
a  0.40 ± 0.001
b  0.40 ± 0.001
b
SBMC (g)  0.28 ± 0.035
a  0.27 ± 0.032
a  0.27 ± 0.048
a  0.26 ± 0.032
a
SBMC (g)
/wt (kg) 
 1.42 ± 0.001
a  1.42 ± 0.001
a  1.41 ± 0.001
a  1.30 ± 0.001
a
1) Mean ± SD
2) Values  with  different  superscript  within  a  column  are  significantly  different  at 
p<0.05  by  Duncan's  multiple  range  test.
Results 
Weight gain and FER
As expected, weight gain for the OVX rats was significantly 
greater than that of SHAM rats (p<0.05). The results of this 
study indicate that body weight gain was higher in OVX groups 
than in SHAM groups regardless of diets. And the weight gain 
for the OVX rats were not lower than that for rats fed 100% 
calcium level as recommended (Table 2). Mean food intake was 
14.52 ± 3.85 g/day and 13.81 ± 1.73 g/day for the control and 
taurine groups within SHAM rats, respectively. No difference 
was found in food intake between control diet and taurine diet 
(Table 2). 
Serum Ca, P, alkaline phosphatase and osteocalcin
The concentrations of serum Ca and P were not significantly 
different among the experimental groups (Table 3). And the 
concentrations of serum alkaline phosphatase and osteocalcin 
were not significantly different among the experimental groups 
(Table 4). 
Urine Ca, P, deoxypyridinoline, creatinine and crosslink value
Urinary calcium excretion between SHAM and OVX groups 
was not significantly different (Table 5). Crosslink values were 
164.4 ± 26.8 and 169.3 ± 36.9 (nM/mM) for the control and 
taurine groups within SHAM group, respectively. Crosslink value 
was increased in ovariectomized groups. Although urinary 
crosslink value was generally higher in the control group than 
in the taurine group (Table 6), the difference was not statistically 
significant. 
Spine and Femur BMD, BMC, BMD per weight and BMC per 
weight
The bone mineral density and bone mineral content data are 
shown in Table 7 and Table 8. The spine BMC and BMD were 
significantly less in rats fed 50% of recommended calcium diet 
than in SHAM and OVX rats fed 100% of recommended calcium 
diet (Choi & DiMarco, 2009). In the control diet, spine BMD 
was significantly lower in OVX rats than in SHAM rats (0.095
± 0.01 and 0.084 ± 0.08 g/cm
2, respectively p<0.05), and in the Mi-Ja Choi 111
Table 8. The effect of diets on femur BMD and BMC, and femur BMD per weight
and BMC per weight in rats fed Ca deficient diet
Sham Ovx
Control Taurine Control Taurine
FBMD (g/cm
2) 0.146 ± 0.008
1)a2) 0.145 ± 0.005
a 0.143 ± 0.005
a 0.137 ± 0.013
a
FBMD (g/cm
2)
/wt (kg) 
 0.72 ± 0.001
a  0.73 ± 0.001
a  0.71 ± 0.001
a  0.71 ± 0.001
a
FBMC (g) 0.276 ± 0.016
a 0.275 ± 0.015
a 0.273 ± 0.017
a 0.265 ± 0.027
a
FBMC (g)
/wt (kg) 
 1.44 ± 0.001
a  1.52 ± 0.001
a  1.40 ± 0.001
a  1.36 ± 0.001
a
1) Mean ± SD
2) Values  with  different  superscript  within  a  column  are  significantly  different  at 
p<0.05  by  Duncan's  multiple  range  test.
taurine group, spine BMD was significantly lower in OVX rats 
than in SHAM rats. They were not significantly different from 
each other within SHAM and OVX groups by taurine 
supplementation (Table 7). 
Mean femur BMD and BMC in the taurine diet group did not 
differ significantly from that in the control diet group in OVX 
rats fed 50% of recommended Ca diet. Also femur BMD/weight 
and BMC/weight of taurine group was not significantly higher 
than that of control group in OVX rats. (Table 8).
Discussion
Osteoporosis is a metabolic bone disease characterized by a 
defect in bone remodeling and the loss of normally mineralized 
bone. Maximum skeletal mass is achieved in young adults at 
18-25 y of age. After age 40, the slow phase of bone loss begins 
in both sexes and continues at a rate of 0.5-1%/y until late in 
life. In women after menopause, there is an additional rate of 
bone loss of 2-3%/y because of the decreasing estrogen 
concentrations associated with aging. Osteoporosis is responsible 
for 1.2 million fractures in the United States annually. The most 
common fractures are of the vertebrae, distal radius, and hip 
(Riggs & Melton, 1986). Bone mineral density (BMD) and bone 
metabolism are affected by genetic, endocrine, mechanical, and 
nutritional factors, with extensive interactions between the 
different factors. Calcium has been reported as the most important 
nutrient associated with peak bone mass (Recker et al., 1992) 
and may be the only one for which there is epidemiological 
evidence of a relation to fracture rate. Low calcium intake is 
particularly common in many countries.
There is a general consensus that dietary calcium moderately 
reduces the rate of cortical bone loss in late menopause (Reid 
et al., 1995; Soroko et al., 1994). A positive association between 
bone density and BMI or body weight has been well documented 
in many large epidemiologic studies (Ravn et al., 1999). 
Bone-protective effects of BMI may increase weight bearing 
(Slemenda, 1995), increase aromatization of androgen to estrogen 
in adipose tissue (Frumar et al., 1980), lower concentrations of 
sex hormone-binding globulin (van Hemert et al., 1989), or 
directly increase bone formation induced by high circulating 
concentrations of insulin (Reid et al., 1995) and other hormones 
secreted by the cells of the pancreatic islets (Reid, 2002).
In recent years, a growing body of observational and clinical 
studies supports a role for dietary calcium and dairy foods in 
controlling body weight and excess adiposity. The investigation 
has shown an inverse relation between calcium intake and body 
weight in older women (Zemel et al., 2000). 
Davies  et al. (2000) and Heaney et al. (2002) reported a 
negative association between calcium intake and body weight, 
body fat, and weight gain in young, middle-aged, and older 
women and calculated that a 300 mg increase in daily calcium 
intake was associated with a 3 kg difference in body weight.
As expected, weight gain for the OVX rats was significantly 
greater than those for SHAM rats (p<0.05). The results of this 
study indicate that body weight gain was higher in OVX groups 
than in SHAM groups regardless of diets. And the weight gain 
for the OVX rats were not lower than that for rats fed 100% 
calcium level as recommended. In recent years, several clinical 
and epidemiologic studies have reported a consistent inverse 
association between calcium intake and body weight (Lin et al., 
2000; Loos et al., 2004). A possible physiologic mechanism 
explaining this relation was recently proposed by Zemel et al. 
(2000), who showed that an increase in intracellular calcium 
concentrations in human adipocytes after stimulation with 
parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D 
[1,25(OH)2D] is able to switch lipid metabolism from lipolysis 
to lipogenesis, which results in an increase in triglycerol storage. 
Consistently, 1,25(OH)2D and PTH have been found to be 
positively associated with body mass index (BMI) (Bell et al., 
1985). Because serum PTH and 1,25(OH)2D concentrations are 
regulated by calcium intake, this metabolic pathway would be 
responsible for the higher risk of overweight and obesity in 
subjects with a low calcium intake and for the weight loss after 
increases in dietary calcium intake.
Bone development requires sufficient amounts of many 
nutrients, but calcium has received the greatest attention because 
of its great mass in the skeleton. Low calcium diet, decreased 
calcium absorption, and increased loss are probably some of the 
most important mechanisms involved in bone loss in aging 
humans. When OVX rats were fed low calcium diet, the decrease 
in calcium absorption due to OVX became significant (Kalu, 
1991) and bone loss was enhanced (Nordin et al., 1979). Low 
calcium diet and OVX have a great potential for weakening the 
bone quality of cortical bone and trabecular bone, respectively, 
and have an additive effect when combined. 
This experiment was originally designed to test the ability of 
a taurine supplement to minimize bone loss during postmenopausal 
model with low calcium intake. Sulfur is predominantly 
responsible for determining the net endogenous acid production 
from protein because it is the acid precursor that is oxidized 
to sulfuric acid (Frassetto et al., 1998). It would therefore make 
sense that a dietary supplement with excess sulfur-containing 
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production in the body. However, these data suggest that bone 
mineral density per weight was increased, without changes in 
bone resorption and bone formation, in the taurine supplemented 
group, and therefore have the potential to increase bone mineral 
density if either the study is extended or more taurine is 
supplemented. The beneficial effect of taurine on ovariectomized 
rats fed calcium deficient diet was not reproduced. Because in 
this study, the control and taurine groups consumed identical 
diets as in the previous study (besides the calcium content), and 
we do not know whether intestinal calcium absorption will be 
increased by more taurine supplement. These results indicate that 
no significant differences in spine and femur BMD were found 
due to 2% taurine diet in OVX rats fed calcium deficient diet 
for 6 weeks. No positive effects of taurine on bone mineral 
density were found in the present study. Our failure to see an 
association between taurine supplementation and bone mineral 
density may have been related to the fact that we used calcium 
deficient diet and the same amount of taurine. Further 
investigations of the relation between taurine and calcium intake 
level for bone mineral density are warranted. 
The results of this study indicate that body weight gain and 
food intake were higher in OVX groups than in SHAM groups 
regardless of diets. There were no differences in weight gain 
between the control and taurine groups in both OVX and SHAM 
groups. Within the OVX groups, serum calcium concentration 
was lower in rats fed taurine than in rats fed the control diet. 
Serum ALP, osteocalcin, urinary calcium, and phosphate were 
not different in each group. Within the OVX group, there were 
no differences in spine BMD and BMC and femur BMD and 
BMC. The beneficial effect of taurine on ovariectomized rats 
fed calcium deficient diet was not reproduced. So the beneficial 
effect of taurine on bone seems different by calcium intake levels.
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